Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
IOVA logo IOVA
Upturn stock ratingUpturn stock rating
IOVA logo

Iovance Biotherapeutics Inc (IOVA)

Upturn stock ratingUpturn stock rating
$3.21
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

04/22/2025: IOVA (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

ratingratingratingratingrating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

12 Analysts rated it

These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.

Year Target Price $10.7

Year Target Price $10.7

Analyst’s Price TargetsFor last 52 week
$10.7Target price
Low$1.64
Current$3.21
high$12.51

Analysis of Past Performance

Type Stock
Historic Profit -5.04%
Avg. Invested days 27
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 04/22/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 564.35M USD
Price to earnings Ratio -
1Y Target Price 10.7
Price to earnings Ratio -
1Y Target Price 10.7
Volume (30-day avg) -
Beta 0.86
52 Weeks Range 1.64 - 12.51
Updated Date 06/29/2025
52 Weeks Range 1.64 - 12.51
Updated Date 06/29/2025
Dividends yield (FY) -
Basic EPS (TTM) -1.22

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -176.49%
Operating Margin (TTM) -245.77%

Management Effectiveness

Return on Assets (TTM) -27.14%
Return on Equity (TTM) -51.85%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 261696457
Price to Sales(TTM) 2.65
Enterprise Value 261696457
Price to Sales(TTM) 2.65
Enterprise Value to Revenue 1.23
Enterprise Value to EBITDA -8.68
Shares Outstanding 333934016
Shares Floating 280347936
Shares Outstanding 333934016
Shares Floating 280347936
Percent Insiders 0.48
Percent Institutions 81.25

Analyst Ratings

Rating 4.08
Target Price 10.7
Buy 3
Strong Buy 5
Buy 3
Strong Buy 5
Hold 4
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Iovance Biotherapeutics Inc

stock logo

Company Overview

overview logo History and Background

Iovance Biotherapeutics, Inc. (IOVA) was founded in 2007. It focuses on developing and commercializing cancer immunotherapies based on tumor-infiltrating lymphocytes (TIL) technology. The company has progressed from preclinical research to late-stage clinical trials, achieving significant milestones in cell therapy for solid tumors.

business area logo Core Business Areas

  • Tumor-Infiltrating Lymphocyte (TIL) Therapy: Iovance's core business is developing and commercializing TIL-based immunotherapies. This involves isolating, expanding, and re-infusing a patient's own immune cells to target and destroy cancer cells.

leadership logo Leadership and Structure

Iovance Biotherapeutics Inc's leadership team includes Frederick Vogt (Interim CEO), Igor Bilinsky (Chief Scientific Officer), and Wayne Rothbaum (Chairman of the Board). The company has a functional organizational structure with departments focused on research, clinical development, manufacturing, and commercialization.

Top Products and Market Share

overview logo Key Offerings

  • Lifileucel (AMTAGVI): Lifileucel is a TIL therapy approved for the treatment of adult patients with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF inhibitor. Its approval date was Feburary 16, 2024. Competitors include traditional melanoma treatments like surgery, radiation, chemotherapy, targeted therapies, and other immunotherapies like PD-1 inhibitors (Keytruda, Opdivo) and CTLA-4 inhibitors (Yervoy). Currently, it holds the first-to-market position for approved TIL therapy in melanoma.

Market Dynamics

industry overview logo Industry Overview

The immunotherapy market is experiencing rapid growth due to its effectiveness in treating various cancers. Cell therapies like TIL are becoming increasingly important, offering potential for durable responses in patients with advanced solid tumors.

Positioning

Iovance is a leader in the TIL therapy field. The companyu2019s first approval in melanoma, sets it up to expand into other solid tumors. Iovance holds a competitive advantage with its established manufacturing processes.

Total Addressable Market (TAM)

The total addressable market for cell-based cancer therapies is estimated in the tens of billions of dollars annually, with projections for continued growth. Iovance is positioned to capture a significant share of this market by expanding the use of its TIL platform to treat various solid tumors and potentially earlier lines of therapy.

Upturn SWOT Analysis

Strengths

  • First approved TIL therapy
  • Proprietary TIL technology platform
  • Experienced management team
  • Advanced manufacturing capabilities
  • Strong clinical data for Lifileucel

Weaknesses

  • High cost of TIL therapy
  • Complex manufacturing process
  • Limited commercial experience
  • Dependence on single product (Lifileucel)
  • Reliance on success in clinical trials for other indications

Opportunities

  • Expand Lifileucel to other solid tumors (e.g., non-small cell lung cancer, cervical cancer)
  • Develop next-generation TIL therapies
  • Partner with other companies to expand market reach
  • Improve manufacturing efficiency to reduce costs
  • Secure favorable reimbursement policies

Threats

  • Competition from other immunotherapy companies
  • Regulatory hurdles and delays
  • Manufacturing challenges and supply chain disruptions
  • Unfavorable clinical trial results
  • Pricing and reimbursement pressures

Competitors and Market Share

competitor logo Key Competitors

  • BMY
  • MRK
  • PFE

Competitive Landscape

Iovance has a competitive advantage with their first-to-market status with a TIL product for melanoma, but faces strong competition from established players with broad immunotherapy portfolios.

Growth Trajectory and Initiatives

Historical Growth: Limited revenue history as it is a pre-commercial company.

Future Projections: Future growth depends on successful launch and commercialization of Lifileucel and clinical trial progress in other indications. Analyst estimates indicate significant revenue growth in the coming years.

Recent Initiatives: FDA approval and commercial launch of Lifileucel, expansion of clinical trials to other solid tumors, and investment in manufacturing capacity.

Summary

Iovance Biotherapeutics is strategically positioned as a pioneer in the TIL therapy market. The recent FDA approval and commercial launch of Lifileucel present a significant opportunity for revenue growth. However, the company faces challenges related to manufacturing complexity and competition from larger pharmaceutical companies. Successful expansion of Lifileucel to other indications and continued investment in research and development will be critical for long-term success.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Iovance Biotherapeutics Inc. Investor Relations
  • SEC Filings
  • Analyst Reports
  • Company Press Releases
  • FDA.gov

Disclaimers:

The information provided is for informational purposes only and should not be considered financial advice. Market data and analyst estimates are subject to change. Investment decisions should be based on thorough research and consultation with a qualified financial advisor.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Iovance Biotherapeutics Inc

Exchange NASDAQ
Headquaters San Carlos, CA, United States
IPO Launch date 2010-10-15
Interim CEO, President, General Counsel, Corporate Secretary & Director Dr. Frederick G. Vogt Esq., J.D., Ph.D.
Sector Healthcare
Industry Biotechnology
Full time employees 838
Full time employees 838

Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic melanoma and metastatic renal cell carcinoma. It develops lifileucel for treatment of melanoma, cervical cancer, non-small cell lung cancer (NSCLC), endometrial cancer, and head and neck squamous cell carcinoma; IOV-2001 to treat chronic lymphocytic leukemia and small lymphocytic lymphoma; IOV-4001 for the treatment of melanoma and NSCLC; and IOV-3001, an antibody cytokine engrafted protein for use in the TIL therapy treatment regimen. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.